Twist Bioscience (TWST) TD Cowen 46th Annual Health Care Conference summary

Strategic financial targets and operational progress

• Targeting Adjusted EBITDA breakeven by Q4 FY2026, with gross margin improved from low 30s to over 50% through increased chip volume and disciplined OpEx management.

• Selective OpEx increases are being made to maximize growth without risking profitability timelines.

• New product launches and expanding the NPI engine have grown the serviceable addressable market (SAM) from $2B in 2020 to $7B, with a goal of $12B by 2030.

AI-driven growth and customer engagement

• AI is driving significant demand in the therapeutics segment, with $111M in revenue and over 25% growth last year.

• Automated, high-throughput DNA/protein production and data delivery address the needs of AI-driven customers for speed, scale, and affordability.

• Competitive differentiation is achieved through faster turnaround (17 days vs. 41–57 days for peers) and extreme automation.

• Customer engagement focuses on expanding reach and delighting clients to drive repeat business and long-term relationships.

Innovation and partnerships

• Licensing of Invenra’s bispecific antibody technology enables easier, automated production and supports AI model development for complex antibodies.

• High bar for future deals, with focus on profitability and strategic fit.